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Nanog Requires BRD4 to Maintain Murine Embryonic
Stem Cell Pluripotency and Is Suppressed
by Bromodomain Inhibitor JQ1 Together with Lefty1
Gillian A. Horne,1,* Helen J.S. Stewart,1,* Jacqueline Dickson,2 Stefan Knapp,3
Bernard Ramsahoye,2 and Timothy Chevassut1
Embryonic stem cells (ESCs) are maintained in an undifferentiated state through expression of the core
transcriptional factors Nanog, Oct4, and Sox2. However, the epigenetic regulation of pluripotency is poorly
understood. Differentiation of ESCs is accompanied by a global reduction of panacetylation of histones H3 and
H4 suggesting that histone acetylation plays an important role in maintenance of ESC pluripotency. Acetylated
lysine residues on histones are read by members of the bromodomain family that includes BET (bromodomain
and extraterminal domain) proteins for which highly potent and selective inhibitors have been developed. In this
study we demonstrate that the pan-BET bromodomain inhibitor JQ1 induces rapid spontaneous differentiation
of murine ESCs by inducing marked transcriptional downregulation of Nanog as well as the stemness markers
Lefty1 and Lefty2, but not Myc, often used as a marker of BET inhibitor activity in cancer. We show that the
effects of JQ1 are recapitulated by knockdown of the BET family member BRD4 implicating this protein in
Nanog regulation. These data are also supported by chromatin immunoprecipitation experiments which confirm
BRD4 binding at the Nanog promoter that is known to require acetylation by the histone acetyltransferase MOF
for transcriptional activity. In further support of our findings, we show that JQ1 antagonizes the stem cell-
promoting effects of the histone deacetylase inhibitors sodium butyrate and valproic acid. Our data suggest that
BRD4 is critical for the maintenance of ESC pluripotency and that this occurs primarily through the mainte-
nance of Nanog expression.
Introduction
Embryonic stem cells (ESCs) exhibit dual uniqueproperties: limitless self-renewal and pluripotency in
differentiation [1]. Murine ESCs cultured in the presence of
the cytokine leukemia inhibitory factor (LIF), which acti-
vates Stat3, are maintained in an undifferentiated state
through the expression of critical transcription factors Oct4
(also known as Pou5f1), Sox2, and Nanog [2]. These factors
form the ESC transcriptional core [3]. Ectopic expression of
Oct4 and Sox2 together with Myc and Klf4 in terminally
differentiated somatic cells can result in reprogramming and
generation of induced pluripotent stem cells [4]. Recently,
the histone acetyltransferase (HAT) known as MOF (also
called MYST1 or KAT8) has been shown to be a key regu-
lator of the ESC transcriptional network and required for
self-renewal [5]. Deletion of Mof results in loss of ESC self-
renewal and induction of differentiation with downregulation
of the transcriptional core factors Oct4, Sox2, and Nanog and
aberrant expression of differentiation marker genes. Over-
expression of Nanog was shown to rescue the Mof null
phenotype suggesting that Nanog is the key downstream
target for MOF and largely mediates its function in ESCs, a
conclusion supported by the considerable overlap of MOF
and Nanog transcriptomes and also the finding that*80% of
Nanog target genes have MOF binding sites [6]. Chromatin
immunoprecipitation (ChIP) analysis has confirmed MOF
binding and H4K16 acetylation at the Nanog promoter, but
not inMof null cells suggesting that MOF, unlike other HATs
such as p300/CBP, TIP60, and GCN5, is able to regulate
Nanog expression [6].
Acetylated lysine residues in histones are specifically
recognized by proteins that contain a small helical interac-
tion module known as a bromodomain [7]. Members of the
BET (bromodomain and extraterminal domain) family of
proteins read the differentially acetylated histones causing
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changes in gene transcription [8,9] and have particularly
high affinity for the tail, including H4K16ac [10]. The BET
family comprises four distinct genes, namely, BRD2, BRD3,
and BRD4, which are ubiquitously expressed, and BRDT,
which is restricted to the testis. Each BET protein contains
two bromodomains, both of which can be prevented from
binding acetyl-lysine by the prototypic bromodomain in-
hibitor JQ1. Enantiomerically pure (+ )-JQ1, hereafter re-
ferred to as JQ1, binds with a Kd of approximately 50 nM
and 90 nM to the first and second bromodomains of BRD4
and BRD3, respectively, whereas BRDT and BRD2 show
about threefold weaker binding [11]. Inhibition of BRD4 by
JQ1 has been shown to induce differentiation and death of
human acute myeloid leukemia and multiple myeloma cells,
possibly through the transcriptional downregulation of MYC
[12–15] or by influencing MYC turnover [16]. In wild-type
mice, JQ1 causes reversible sterility by inhibition of BRDT
[17]. However, the effect of JQ1 on ESCs has not been
previously reported.
In this study, we show that pharmacological inhibition of
BRD4 and BRD4 knockdown causes morphological differ-
entiation of ES cells. Microarray analysis of ES cells treated
with JQ1 causes a robust downregulation of Nanog with
little effect on the pluripotency genes Sox2, Oct4, and klf4.
Furthermore, we show that this effect is mediated by BRD4
and that BRD4 binds to the Nanog promoter suggesting that
BRD4 induces differentiation of murine ESCs through
downregulation of Nanog.
Materials and Methods
Materials
DMEM, penicillin/streptomycin, and L-glutamine were
from Fisher. Anti-Nanog and anti-BRD4 antibodies were
from Bethyl laboratories, anti-c-MYC was from New Eng-
land Biolabs. Taqman probes were from Applied Biosys-
tems. Taq polymerase and wst-1 were from Roche. The
Alkaline phosphatase kit, Leukemia inhibitory factor (LIF),
trichostatin A (TSA), valproic acid, sodium butyrate, non-
essential amino acids, and two mercaptoethanol were from
Sigma. The HiPerFect and the Quantitect cDNA synthesis
kit were from Qiagen. The pCMV Nanog expression plas-
mid was a kind gift from Professor Austin Smith (University
of Cambridge). The LTx transfection reagent was from Life
Technologies. Anti-acetylated histone H3 and acetylated
histone H4 were from Millipore. Anti-SSEA1 (clone
MS480) was from the Developmental Hybridoma Bank.
Embryonic stem cells
E14 ESCs were kindly provided by Dr Lesley Forrester
(University of Edinburgh) and derived from the inbred
mouse strain 129/Ola in 1985 by Dr Martin Hooper [18].
Early passage cells were used (< 20 passages). The cell line
was maintained in vitro and propagated in DMEM supple-
mented with 10% FBS, 100 nM L-glutamine, 100 IU/mL
penicillin, 100 IU/mL streptomycin, 1% nonessential amino
acids, 50mM 2-mercaptoethanol, and 100 IU/mL of LIF.
This medium is referred to as LIF-positive medium to dis-
tinguish it from LIF-negative medium that was used to in-
duce ESC differentiation. Cells were incubated at 37C in a
humidified atmosphere containing 95% air and 5% CO2.
Compounds and experimental conditions
( + )-JQ1 (referred hereafter as JQ1) and the inactive en-
antiomer ( - )-JQ1 was synthesized according to the pub-
lished synthetic route [11]. Stock dilutions of 10mM in
dimethylsulfoxide (DMSO) were made and stored at
- 20C. Dilutions to working concentrations were made with
phosphate buffered saline (PBS) and also stored at - 20C.
The appropriate DMSO dilution and the inactive enantiomer
( - )-JQ1 were both used as negative controls. HDAC in-
hibitor concentrations used were 0.5mM valproic acid and
0.2mM sodium butyrate.
Alkaline phosphatase assay
The Alkaline phosphatase staining was performed using a
Sigma-Aldrich kit (procedure no 85). Cells were plated on
coverslips at 2.5 · 104 and 5 · 104 per well. Cells were
treated with varying concentrations of JQ1 and analyzed
after 72 h culture in LIF-positive medium. Cells were fixed
by immersing in citrate buffered acetone for 30 s and in-
cubated in an alkaline-dye mix (naphthol AS-MX phosphate
alkaline solution and diazonium salt solution) for 30min.
ESC differentiation was evaluated morphologically and
photomicrographs were produced.
Immunocytochemical analysis
Cells were plated on gelatin-coated coverslips at 2.5 · 104
cells per well in 24 well plates in 400 mL of LIF-positive
medium in the presence or absence of 0.5 and 1mM for 72 h.
Preparations were fixed in 4% paraformaldehyde for 15min
then permeabilized with 0.2% TritonX100 for 3min. Pri-
mary antibodies were applied for 1 h at room temperature.
After washing thoroughly with PBS, cells were incubated
in Alexa fluor-linked secondary antibodies for 30min.
After the final wash through PBS the slides were incubated
in 0.1 mg/mL DAPI (4¢,6-diamidino-2-phenylindole) for
5min then mounted in antifade mounting medium and
viewed by fluorescence microscopy using a Leica DM
5000B microscope fitted with a Leica DPC300FX digital
camera. To illustrate the intensity of immunolabeling,
digital images were captured at identical exposure times. In
the case of the global histone acetylation immunolabeling
experiment, semiquantitative analysis was performed by
antibody titration.
Western blot analysis
E14 ESC were treated with 0.5 or 1 mM JQ1 for 24 h then
harvested. Proteins were extracted in sample buffer con-
taining protease inhibitor tablets. Samples were then diluted
in loading buffer (with b-mercaptoethanol), boiled for
5min, and subjected to gel electrophoresis on 10% SDS-
polyacrylamide gels. A total of 36mg of cell extract was
loaded per lane. Proteins were electrophoretically trans-
ferred onto a PVDF membrane for 1 h at 150mA constant
current. Membranes were blocked with 5% milk for 1 h at
room temperature and then rotated overnight at 4C with
primary antibody diluted 1:2,000 in TBS 0.1% Tween.
HRP-linked secondary antibodies were used at a dilution of
1:20,000 for 1 h. Blots were developed using a Vectastain
ABC kit or a chemiluminescent detection kit.
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Quantitative RT-PCR
Total RNA was extracted from ESCs using the TRIzol
reagent according to the manufacturer’s instructions. RNA
(1 mg) was reverse transcribed using a QuantiTect cDNA
kit and the PCR reactions were performed using the Taq
Man Gene Expression Assays (Applied Biosystems)
c-MYC (Mn00487804_m1), Nanog (Mm02384862_g1),
GAPDH (Mn99999915_g1), MYST-1 (Mn00458911_m1),
Pou5f1 (Mn03053917_g1), RPS18 (Mn02601778_g1), Lef-
ty1 (Mn03053915_s1) using the standard TaqMan reagents,
and protocols on a MX3500 (Stratagene) qRT-PCR machine.
The DDCt method was used for relative expression quan-
tification using the average cycle threshold for GAPDH
RNA and 18s RNA to normalize gene expression levels
between samples. All experiments were performed in trip-
licate repeats and expression levels were compared between
JQ1 and ( - )-JQ1-treated cells using a two-tailed t test with
P values £ 0.05.
Gene transcriptional profiling
Mouse ESCs were treated with 1mM JQ1 or 1mM (- )-JQ1
for 16 h in quadruplicate experimental replicates. RNA was
extracted with the TRIzol reagent and analyzed using an
Agilent 2100 bioanalyzer. All RNA used had a RIN value of
greater than 8.0. Transcriptional profiling for control and
JQ1-treated ESCs was performed using the Illumina expres-
sion microarrays. Normalization of the raw data included a
variance stabilizing transformation followed by robust spline
normalization using the R package Lumi. The expression
changes of genes were calculated by comparing the mean
expression levels of treatment versus control untreated.
Of note, the Illumina array used in the transcriptional
profiling experiments was the MouseWG-6 v2.0 Expression
BeadChips system, which allows 12 samples per array,
thereby allowing all three quadruplicate experimental sam-
ples to be analyzed on a single array. The complete ex-
pression dataset is available through the MIAME-compliant
GEO (Gene Expression Omnibus) NCBI public repository.
Transfection of cell lines with siRNAs
For siRNA studies, ESCs were seeded in 24-well plates at
a density of 250,000 cells per well. Twenty-four hours after
plating, cells were transfected with 37.5 ng ON-TARGET-
plusSMARTpool siRNA (Thermo Scientific) targeting
BRD4 or a nontargeting scrambled control using the Hi-
PerFect Transfection Reagent according to the manufac-
turer’s instructions. RNA was prepared from cells 24 h after
transfection.
CHiP analysis
E14 ESC were grown to 80% confluence before being
treated with ethanol, 1 mM JQ1 or (- )-JQ1 for 24 h. Cells
were crosslinked with 1% formaldehyde at 37C for 10min,
and sonicated for 12 · 20 s with 1min intervals at 2Am
(Soniprep 150; MSE, Sanyo Gallenkamp PLC). Chromatin
was precleared with 1mg anti-rabbit IgG, 2 mg sheared sal-
mon sperm DNA, and 50 mL of 50% protein-A-Agarose
slurry for 4 h at 4C. Immunoprecipitation was performed
overnight at 4C with 2 mg sheared salmon sperm DNA,
50mL protein-A-Agarose, and either rabbit anti-Brd4 (Santa
Cruz) or rabbit IgG. DNA fragments were amplified using
the FastStart Universal SYBR-Green Master Mix (Roche
Diagnostics) and previously published primers targeting the
Nanog and GAPDH promoters [19]. Results are shown as a
percentage of the input DNA.
Generation of Nanog overexpressing ESCs
ESCs plated in LIF+ ve medium were transfected with
6 mg of pCAG-Nanog expression vector or control vector
using the LTx reagent. Transient transfectants were used in
experiments 24 h after transfection. Stable transfectants
were made by selecting cell cultures with 300mg/mL hy-
gromycin for 10 days.
Statistical analysis
Results of each experiment represent mean – standard
deviation (SD) of replicate experiments. Differences were
determined using the Student’s t-test. When there was a
prior hypothesis results were considered significant when
P< 0.05. When there was no prior hypothesis and multiple
tests were performed (microarray analysis), we also derived
q values of significance using the Benjamini–Hochberg
method.
Results
JQ1 induces differentiation of ESCs accompanied
by downregulation of Nanog
Initial experiments were conducted to study the effect of
JQ1 on ESCs cultured in LIF-containing medium. Using
concentrations of JQ1 up to 1 mM we observed clear dose-
dependent morphological changes over 72 h. JQ1-treated
cells became flattened and elongated with reduced cell-to-
cell contact and a fibroblastic morphology similar to cells
grown in LIF-negative medium whereas cells grown in LIF-
positive medium remained undifferentiated in small,
spherical, well-delimited three dimensional phase-bright
clusters (Fig. 1A). In further experiments, we demonstrated
that exposure of ESCs to 1 mM JQ1 for as little as 6 h is
sufficient to induce morphological differentiation indicating
that JQ1 causes rapid differentiation of ESCs despite con-
tinued presence of LIF. Importantly, removal of JQ1 from
the medium for 72 h did not reverse ESC differentiation.
The ( - )-JQ1 inactive enantiomer had no discernible mor-
phological effect on the cells.
We confirmed these observations by staining for alkaline
phosphatase, a well-established marker of the undifferenti-
ated state. This revealed that JQ1 treatment had caused a
dose-dependent reduction in alkaline phosphatase expres-
sion when compared with untreated ESCs. The ( - )-JQ1
enantiomer had no effect. These data show that JQ1 treat-
ment promotes morphological differentiation of ESCs re-
sulting in an apparent loss of pluripotency (Fig. 1A).
Interestingly, the JQ1-treated ESCs retained expression of
the embryonic surface marker SSEA1 at the 72 h time point
used in this experiment (Fig. 1A). Importantly, induction of
ESC differentiation by JQ1 occurred without any significant
effect on cell viability up to a concentration of 1 mM as
assessed by WST-1 proliferation assay (data not shown).
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To further explore the role of BET proteins in stem cell
maintenance we conducted immunocytochemistry of ESCs.
This confirmed that BRD4 exhibits ubiquitous nuclear ex-
pression in both control and JQ1-treated ESCs (Fig. 1B). We
also performed immunocytochemistry for Nanog given its
role in maintenance of the core transcriptional network. This
clearly demonstrated marked reduction in expression of
Nanog in JQ1-treated ESCs suggesting that this gene had
been significantly downregulated (Fig. 1B). Taken together,
the addition of JQ1 to ESC cultures interferes with several
characteristics of stem cells, including morphology and al-
kaline phosphatase staining, and that this is accompanied by
loss of expression of Nanog suggesting that BET proteins
are required for maintenance of the undifferentiated ESC
phenotype.
BET bromodomain inhibition leads to Nanog
downregulation in ESCs
To explore possible transcriptional deregulation of ESCs
by JQ1, we performed expression profiling microarray ex-
periments. We treated ESCs cultured in LIF-containing
medium for 16 h with either JQ1, the inactive enantiomer
( - )-JQ1 (both at 0.5 mM), or vehicle only. We found that
JQ1 had significant effects on the ESC transcriptome, 5,697
of the 30,854 genes (18.4%) on the array being significantly
deregulated (two-tailed t-test, P < 0.05). Compared with
vehicle only, 92 genes were differentially downregulated
and 42 genes were differentially upregulated by greater than
two-fold change for JQ1 with no significant transcriptional
changes for ( - )-JQ1. This data is illustrated by way of
heatmaps for both compounds showing the relative expres-
sion level changes for the most significantly deregulated
genes (n = 1,113 genes at significance level of P < 0.001) in
Fig. 2A. Further analysis of these genes showed that the 50
that were most significantly deregulated (two-tailed t-test,
P < 2.24E-06) were significantly downregulated compared
with the rest (mean log2 = - 0.6084 versus - 0.0026, re-
spectively, P = 9.6E-11, two-tailed t-test). This, together
with the fact that twice as many genes were downregulated
by greater than two-fold than upregulated, suggests that the
predominant effect of JQ1 is to induce transcriptional
downregulation of genes. While upregulated genes were
observed in the analysis, the extent of the changes was less
and the statistical significance of those changes was reduced
when compared with the downregulated genes (Fig. 2B).
Nanog was markedly downregulated by 70.3% as as-
sessed by microarray profiling consistent with our im-
munolabeling data. Interestingly, the most downregulated
gene was Lefty1 (87.7%, q = 7.1 · 10 - 4) with Lefty2 and
Nodal also significantly downregulated (66.7%, q = 3.4 ·
10 - 3 and 45.4%, q = 0.008, respectively). Other notable
genes downregulated by JQ1 were the pluripotency marker
genes Fbx15 and Rex1 (78.9%, q = 1.6 · 10 - 3 and 56.7%,
q = 0.02, respectively). By contrast, expression of Oct4 was
modestly downregulated by 36.3% (q = 0.05) whereas the
other core pluripotency genes Sox2 and Klf4 were not sig-
nificantly affected. Importantly, and in contrast to published
FIG. 1. Effect of JQ1 on embryonic stem cells (ESCs). (A) Phase contrast micrograph of ESCs grown in LIF-containing
medium exposure to 1 mM JQ1 for 72 h showing morphology (upper panel) and alkaline phosphatase staining (middle
panel) and immunolabeling of SSEA1 (lower panel); (B) BRD4 immunolabeling of control and JQ1-treated ESCs with
DAPI counterstain (upper panel) and Nanog immunolabeling showing JQ1-induced downregulation (lower panel). Color
images available online at www.liebertpub.com/scd
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FIG. 2. JQ1 induces transcriptional deregulation of genes. Microarray profiling was performed using the Illumina plat-
form to assess the transcriptional effects of 1 mM JQ1 and ( - )-JQ1 at 16 h on ESCs. (A) Heatmaps (derived from the
analysis of 4 replicates) showing expression level changes for the most deregulated genes (n = 1,113 genes at t-test
significance level of P < 0.001) ordered by degree of deregulation (green = up; red= down); (B) heatmaps of the most
significantly deregulated genes ordered by P values ( JQ1 versus untreated control, two-tailed t-test) with analysis of the 50
most deregulated genes (*) revealing a predominant downregulatory effect compared with the rest (mean log2 - 0.6084
versus - 0.0026, respectively, P= 9.6 · 10- 11, two-tailed t-test); (C) effect of JQ1 on transcription of germ layer-specific
genes; (D) effect of JQ1 on selected pluripotency-related genes; (E) confirmatory qRT-PCR analysis of cDNA samples
prepared from ESCs treated with 0.5 mM for up to 24 h was performed for Nanog, Lefty1, Mof, and Myc; (F) quantification
of mRNA transcript levels for Fbox15, klf4, Oct4, Sox2, and Zfp42 was performed by qRT-PCR (data are representative of
at least three independent experiments performed in triplicate–SD). Color images available online at www.liebertpub.com/scd
(Figure continued/)
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observations in leukemia and myeloma cell lines, we find
that c-Myc was not significantly affected by JQ1 in ESCs
where it is weakly transcribed suggesting this gene is not in-
variably downregulated by BET bromodomain inhibition. Of
note, JQ1 upregulatedMof/Myst1 by 37.9% (q= 0.01) and also
the BET gene Brd2 by 118% (q= 0.006). Brd3 and Brd4 were
upregulated by 14.5% and 36.7%, respectively, but these latter
differences were not statistically significant (q> 0.05). These
results are summarized in Table 1.
To explore possible lineage-specificity of JQ1-induced
ESC differentiation, we analyzed the microarray profil-
ing data to explore transcriptional markers specific for the
embryonic germ layers. This revealed a tendency to upre-
gulation of ectodermal markers and a concomitant down-
regulation of endodermal markers (Fig. 2C). Further analysis
of pluripotency-related genes, and their fold change with
JQ1, is shown in Fig. 2D.
We confirmed the key microarray findings outlined above
by qRT-PCR (Fig. 2E, F). A time course of JQ1 treatment of
ESCs demonstrated a dramatic decrease in expression of
both Nanog and Lefty1 genes with maximal downregulation
occurring at 8–24 h. By contrast, levels of the HAT Mof/
Myst1 were modestly increased by JQ1 over the same time
course, whereas levels of c-Myc were largely unaffected by
JQ1. Fbox15 and Zfp42 were also seen to be downregulated
after 24 h JQ1 treatment, whereas the pluripotency genes
Klf4, Oct4, and Sox2 were unaffected. The observation that
morphological changes were first apparent several hours
after Nanog downregulation suggests that inhibition of BET
bromodomain proteins by JQ1 suppresses Nanog expression
FIG. 2. (Continued).
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resulting in ESC differentiation. This is supported by the
finding that downregulation of both Nanog and Lefty1 in
ESCs was more pronounced after 24 h of JQ1 exposure than
seen in ESCs following LIF withdrawal, where onset of
morphological differentiation occurs over a longer time
course (data not shown).
JQ1-induced differentiation of ESCs
is independent of MYC
Based on the observations that JQ1 reduces levels of
MYC in drug-sensitive cell lines and primary samples de-
rived from hematological malignancies (AML and MM), we
investigated whether JQ1 suppresses c-Myc expresssion in
ESCs. Microarray results from JQ1-treated cells showed no
significant effect on c-Myc transcripts, a result that was
largely corroborated by qRT-PCR (Fig. 3A). Furthermore,
western blotting showed that MYC protein levels were not
significantly regulated by 24 h of 1 mM JQ1 exposure (Fig.
3B). Thus we show, that in murine ESCs, the mechanism of
JQ1-induced differentiation is independent of MYC.
Nanog overexpression prevents JQ1-induced
ESC differentiation
Nanog is a highly divergent homeodomain-containing pro-
tein that occupies a central position in the core transcriptional
network to maintain pluripotency of ESCs. We, therefore,
sought to test whether ectopic overexpression of Nanog was
able to overcome JQ1-inducedESCdifferentiation.Weusedan
expression vector in which the Nanog gene has been cloned
downstream of a constitutively active chicken actin/globin
promoter (pCAG-Nanog, or pNanog) designed for robust ex-
pression in ESCs (kind gift from Professor A. Smith). Both
transient and stable transfection experiments were performed
using a pCMVeGFP vector as the control. We observed that
transient transfection of the Nanog expression vector signifi-
cantly prevented ESC differentiation by 1mM JQ1 at 24h as
FIG. 3. JQ1 downregulates Nanog
and Lefty1, but not c-Myc in ESCs.
ESCs were treated with 1mM JQ1 for
24h then analyzed: (A) Quantification
of mRNA transcript levels for Lefty1,
Mof, Nanog, and c-Myc was performed
by qRT-PCR (data are representative of
at least three independent experiments
performed in triplicate–SD); (B)
Quantification of protein levels of Na-
nog and MYC was performed by
western immunoblot analysis (blots
were probed with GAPDH antibodies
as a loading control).
Table 1. Microarray Data Showing the Effect of JQ1 on Expression of Selected Genes
Gene
function
Gene
(selected
genes
shown)
Rank total
genes on
array =
30,854)
Control
Av. gene
expression
JQ1
Av. gene
expression
(- )-JQ1
Av. gene
expression
Log2
change JQ1
vs control
( + up;
- down)
% change
gene
expression
JQ1 vs
control
Benjamini–
Hochberg
derived q-values
for multiple
testing
Pluripotency
genes
Nanog 24 699 207 740 - 1.753 70.3% down N/A
Fbx15 7 1,321 279 1,256 - 2.245 78.9% down q = 1.6 · 10- 3
Rex1 55 1,113 482 1,275 - 1.206 56.7% down q = 0.02
Embryonic
patterning
genes
Lefty1 1 706 87 676 - 3.028 87.7% down q = 7.1 · 10- 4
Lefty2 29 234 78 187 - 1.585 66.7% down q = 3.4 · 10- 3
Nodal 139 568 310 610 - 0.873 45.4% down q = 0.008
Bromodomain
BET family
genes
Brd4 30,345 184 252 181 + 0.451 36.7% up q > 0.05
Brd2 30,832 497 1,084 482 + 1.125 118.0% up q = 0.006
Brd3 29,011 554 635 545 + 0.195 14.5% up q > 0.05
Brdt 20,820 79 80 79 + 0.020 1.4% up N/S
Pluripotency core
transcriptional
genes
Oct4 318 3,284 2,092 3,544 - 0.651 36.3% down q = 0.05
Sox2 27,978 129 139 126 + 0.114 8.2% up N/S
Klf4 1,312 122 101 122 - 0.007 17.2% down N/S
Mof 30,380 293 404 301 + 0.466 37.9% up q = 0.01
Myc 27,965 83 90 84 + 0.113 8.1% up N/S
Transcriptional profiling was performed using the Illumina microarray platform. ESCs were exposed to JQ1 or ( - )-JQ1 or vehicle only
for 16 h in independent quadruplicate experiments. Average gene expression data is shown with log change for JQ1 versus control and t-
test. Percentage up or downregulation of the gene has been calculated and the P values have been subjected to a Benjamini–Hochberg
correction for multiple testing of genes other than Nanog (N/A= not applicable; N/S = not significant). Lefty1 was the most downregulated
gene. Selected other genes are shown, including ESC core transcriptional factors, BET protein family members, and various genes involved
with embryonic patterning and pluripotency.
ESC, embryonic stem cell; BET, bromodomain and extraterminal domain.
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assessed by morphology and alkaline phosphatase staining
suggesting that JQ1-induced ESC differentiation results pri-
marily from downregulation of the endogenous Nanog pro-
moter (Fig. 4A). In further experiments, we generated stable
pCAG-Nanog transfectants by pooling hygromycin-resistant
ESC clones at 10 days posttransfection. As for the transient
transfection experiment, the stable transfectants were clearly
refractory to JQ1-induced differentiation. After exposure to
1mM JQ1 for 24h, the effects on Nanog gene expression were
analyzed by qRT-PCR (Fig. 4B). While we found near-si-
lencing of the endogenous Nanog in the control-transfected
ESCs, Nanog expression persisted in the stable transfectants
where the gene was under transcriptional control of the con-
stitutive CAG promoter. Taken together, our results suggest
that the Nanog locus is a major functional target of BET bro-
modomain proteins in ESCs and required for maintenance of
pluripotency.
Nanog is a transcriptional target of BRD4 in ESCs
Based on the fact that JQ1 has greater selectivity and
bromodomain inhibitory activity for BRD4 than other mem-
bers of the BET protein family [11], we hypothesized that this
was the major effector of JQ1-induced ESC differentiation.
We carried out RNAi experiments using Brd4-specific siR-
NAs. Twenty-four hours after transfection, a profound effect
on ESC morphology was observed (Fig. 5A) with Brd4
siRNA-transfected cells having a differentiated morphology
compared with the scrambled siRNA control. The qRT-PCR
analysis revealed approximately 80% knockdown of Brd4
with a concomitant 70% knockdown of Nanog gene expres-
sion (Fig. 5B).
Next, we performed chromatin immunoprecipitation
(ChIP) analysis to measure BRD4 binding to acetylated
histones at the Nanog promoter to understand JQ1-in-
duced transcriptional changes. We found that JQ1 caused
approximately 40–50% reduction in BRD4 binding
compared with the ( - )-JQ1 negative enantiomer and also
the mock control (both experiments performed twice)
suggesting that JQ1 does indeed disrupt BRD4 binding at
the Nanog promoter. This finding suggests that histone
acetylation at the Nanog promoter is critically involved
in gene transcription through recruitment of BRD4
(Fig. 5C).
FIG. 4. Overexpression of Nanog attenuates JQ1-induced downregulation of Nanog. (A) Photomicrographs showing
morphology (above) and alkaline phosphatase staining (below) of ESCs transfected with pNanog (CAG vector) or pControl
(empty vector) and treated with JQ1. (B) Nanog expression levels of stably transfected ESCs showing effect of JQ1 at 1mM for
24h as determined by qRT-PCR. (LIF- vs. LIF+ vs. LIF+ /JQ1 for pNanog and pControl ESCs). Data are representative of at
least three independent experiments performed in triplicate–SD. Color images available online at www.liebertpub.com/scd
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Histone deacetylase inhibitors can overcome
JQ1-induced differentiation
As JQ1 blocks binding of BET bromodomain proteins to
acetylated histones, we investigated the activity of JQ1
with a number of histone deacetylase (HDAC) inhibitors.
We employed two HDAC inhibitors, namely sodium bu-
tyrate and valproic acid, both with activity against class I
and II HDACs [20]. We hypothesized that exposure to
HDAC inhibitors at pluripotency maintaining concentra-
tions might rescue JQ1-induced differentiation through
histone hyperacetylation. In initial experiments we deter-
mined that 0.5 mM JQ1 had no significant effect on global
histone H3 and H4 acetylation as assessed by semiquan-
titative immunocytochemistry using antibody titration
(Fig. 6A).
We next studied the effects of combined JQ1 exposure and
HDAC inhibition on ESC morphology. We observed that
JQ1-induced morphological changes were less pronounced in
the presence of 0.2mM sodium butyrate or 0.5mM valp-
roic acid suggesting functional antagonism between JQ1 and
low-dose HDAC inhibition. Of note, neither of the HDAC
inhibitors alone had any discernible effects on ESC mor-
phology although higher concentrations of sodium butyrate
(2mM) did induce differentiation (Fig. 6B).
Discussion
Recent studies have highlighted the importance of histone
acetylation in the regulation of ESC pluripotency [6,21–23].
This epigenetic modification is read by a family of proteins
containing bromodomains (BRDs) that recognize acetylated
FIG. 5. Brd4 knockdown induces ESC differentiation and downregulation of Nanog. (A) Phase contrast micrographs of
ESCs transfected with scramble siRNA control versus Brd4-specific siRNA. (B) Graph showing level of Brd4 knockdown
and effect on Nanog expression compared with siRNA control as determined by qRT-PCR. (C) Chromatin immunopre-
cipitation of BRD4 at the promoter regions of Nanog and GAPDH in ESC following 24 h growth in the presence of 1 mM
JQ1 or ( - )-JQ1, or following mock manipulation with ethanol. Enrichment is shown as a percentage of input, and in
comparison to IgG enrichment. Data are representative of two independent experiments performed in triplicate – SD.
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lysine residues such as those on certain proteins [24–26] and
the N-terminal tails of histones [8]. Inhibition of the bromo-
domain–acetyl histone interaction, therefore, represents a
novel mechanism of disrupting the epigenetic state of ESCs
that underpins maintenance of self-renewal. In this article, we
studied the effects of the bromodomain inhibitory molecule
JQ1, which primarily inhibits members of the BET family of
proteins [11], on ESCs to investigate the role of histone
acetylation in the maintenance of stem cell pluripotency. We
found that JQ1 induces differentiation of ESCs and over-
comes the pluripotency-promoting effects of LIF as assessed
by morphological, biochemical, and gene expression criteria.
Central to this finding, we show that inhibition of BET bro-
modomain activity by JQ1 leads to downregulation of the
core transcription factor Nanog at both the transcriptional and
protein level. Given the greater affinity of JQ1 for BRD4
compared with BRD2 and BRD3 (Kd values of 49 nM versus
128 and 82nM, respectively), we hypothesized that inhibition
of BRD4 in particular mediates the effect of JQ1 on ESCs.
Microarray analysis demonstrated that the most signifi-
cant effect of JQ1 on transcription was to induce down-
regulation of active genes with twice as many genes being
significantly downregulated than upregulated. As JQ1 in-
hibits the binding of BET bromodomains these data suggest
that the primary purpose of this binding to acetylated his-
tones is to induce gene transcription. In addition to Nanog,
microarray analysis of JQ1-treated cells also revealed sig-
nificant downregulation of other notable genes of interest,
including Lefty1, Lefty2, and Nodal, involved in embryonic
patterning and left–right determination, and Fbx15 and
Rex1, well-recognized markers of ESC pluripotency.
Analysis of germ lineage-specific genes showed that JQ1
induces a shift toward ectodermal differentiation and away
from endodermal differentiation. Our experiment used ESCs
exposed to JQ1 for 16 h. In view of the fact that transcrip-
tional changes seen in ESCs following LIF withdrawal
mostly occur at 48–72 h [6,21–23], we predict that the
changes we observe with JQ1 would likely increase over
time to establish a more definitive skew toward ectodermal
differentiation.
In contrast to the downregulation of Nanog, we found that
the expression of the other core pluripotency transcription
factors Sox2 and Klf4 was not significantly altered whereas
Oct4 was modestly suppressed by JQ1. Likewise, no sig-
nificant downregulation of c-Myc expression was observed
at either the transcriptional or protein level. These results are
in contrast to several other studies of JQ1 on hematological
cancer cell lines in which downregulation of MYC has been
identified as the principal mechanism of action of BET
bromodomain inhibitors. In these cells, ChIP experiments
reveal that BRD4 actively binds to the MYC promoter and
regulates signaling events leading to transcript elongation
[12,14,15]. In response to BET inhibitors, BRD4 is released
from acetylated histones at the MYC locus leading to
transcriptional downregulation [15]. However MYC down-
regulation is neither necessary nor sufficient for the anti-
proliferative effects of BET bromodomain inhibitors: JQ1
induces MYC downregulation in the leukemia cell lines
K562 and Jurkat and the breast cancer cell line MDA MB-
231 without causing apoptosis [12,27]. Furthermore MYC is
not downregulated in JQ1-sensitive lung cancer cell lines
and in one cell line it is significantly upregulated [28].
FIG. 6. JQ1 does not affect histone acetylation, but does antagonize HDAC inhibition in ESCs. (A) JQ1 has no significant
effect on global histone H3 and H4 acetylation in ESCs. ESCs were cultured in the presence or absence of LIF (to induce
differentiation) or in medium containing 1 mM JQ1 plus LIF for 24 h, then immunolabeled with antibodies against acetylated
histone H3 or H4. (B) JQ1 overcomes the effects of low-dose HDAC inhibitors on ESCs. Morphological appearance by
phase microscopy of ESCs cultured for 24 h in LIF-containing medium in the presence of: (a) no drug; (b) 0.5 mM JQ1; (c)
0.2mM sodium butyrate; (d) 0.2mM sodium butyrate plus 0.5 mM JQ1; (e) valproic acid 0.5 mM; (f) valproic acid 0.5 mM
plus 0.5 mM JQ1. Color images available online at www.liebertpub.com/scd
888 HORNE ET AL.
In many previous studies, the effect of BET bromodo-
main inhibitors has been examined in the context of its
antiproliferative effects. In our study, however, we show
that JQ1 has minimal effect on ESC proliferation, but rather
induces differentiation even when the cells are cultured in
the presence of the pluripotency factor LIF. JQ1, through
BRD4 inhibition, has been shown to induce markers of
differentiation in some leukemia cell lines and primary bone
marrow samples. Furthermore in NUT midline carcinoma,
where a translocation results in fusion between BRD4 and
NUT (nuclear protein in testis) genes, application of JQ1
decreased cell proliferation and the expression of BRD4
target genes and increased cellular differentiation suggesting
that JQ1 may have therapeutic effects for this rare disease
[29]. Our RNAi experiments using Brd4-specific siRNAs
show that Brd4 knockdown induces morphological differ-
entiation of ESCs and downregulation of Nanog. Therefore,
it would appear that the effects of JQ1 on ESCs are medi-
ated primarily through inhibition of BRD4 binding to
acetylated histones within the Nanog promoter. While our
experiments were conducted using transient BRD4 knock-
down, this is not the same as producing a stable knockdown/
knockout of BRD4, although we anticipate that such an
experiment would yield similar findings. In addition, while
BRD4 knockdown alone appears to be sufficient in inducing
the morphological effects of JQ1 on ESCs, it is likely that
inhibition of BRD2 and BRD3 may contribute to the tran-
scriptional deregulation of genes observed on microarray
profiling.
Our data clearly reveal an important role for BET bro-
modomain proteins in the maintenance of the pluripotent
state of ESCs through binding to acetylated histones at
discrete gene loci, notably Nanog. The importance of the
acetylation status of histones has been demonstrated in
several studies [6,30,31]. Although the majority of these
studies suggest that histone acetylation is important in the
maintenance of the pluripotent state, others suggest that
histone acetylation increases during differentiation [21].
Over the limited time period of our experiment (48 h) no
apparent change in global H3 and H4 acetylation levels were
found in ESCs induced to differentiate with JQ1 showing
that JQ1-induced ESC differentiation is not mediated
through a global reduction of histone acetylation.
Profound defects in ESC differentiation have been ob-
served after knockdown or knockout studies involving
several HAT genes, including Tip60 [32,33], p300 [32,33],
and Mof [5], and also the HAT cofactor Trrap [22,34].
Furthermore one study shows that differentiation of ESCs is
accompanied by a global reduction in pan-acetylation of
histones H3 and H4 [6]. The effect of HDAC inhibitors on
ESC differentiation is less clear as it has been reported that
they can promote either self-renewal or differentiation de-
pending on the concentrations used [27,35]. It has been
suggested that HDAC inhibitors exert an antidifferentiation
effect when low doses are applied on cells that have already
exited from self-renewal either as embryoid bodies or epi-
blast-like cells, whereas higher doses applied on undifferen-
tiated cells provoke differentiation [35]. In our experiments,
we found that JQ1-induced differentiation of ESCs was re-
duced in the presence of low-dose sodium butyrate or val-
proic acid suggesting functional biological antagonism. We
speculate that low-dose HDAC inhibition induces histone
hyperacetylation at relevant genomic loci to which BET
proteins bind, including potentially Nanog, leading to some
weakening of the bromodomain inhibitory action of JQ1.
The other notable finding from our work was the dem-
onstration that JQ1 is a potent downregulator of Lefty1
(most downregulated gene by microarray) and its homo-
logue Lefty2 in ESCs. Lefty1 and Lefty2 are both divergent
members of the transforming growth factor-b (TGF-b) su-
perfamily of proteins that function as diffusible morphogens
involved in left–right determination and give rise to em-
bryonic asymmetry [36]. Both proteins have been previously
recognized as stemness markers in undifferentiated ESCs
and in blastocysts. Moreover, Lefty1 and Lefty2 have been
implicated in the maintenance of self-renewal and plur-
ipotency of mouse ESCs and optimal expression of both
genes appears to be critical for the balanced differentiation
of ESCs into three germ layers [37]. In particular, Lefty1
knockdown in ESCs has been shown to result in enhanced
phosphorylation of Smad2 and increased differentiation,
which supports our own findings and suggests that JQ1-
induced differentiation of ESCs may be mediated by Lefty1
downregulation as well as by Nanog. Taken together, we
hypothesize that BET family proteins are fundamentally
involved with embryonic patterning and left–right determi-
nation, an assertion supported by the observation that Nodal
is also significantly downregulated by JQ1 in ESCs.
In summary, our results implicate members of the BET
bromodomain family of proteins in the maintenance of ESC
self-renewal and pluripotency primarily through the ex-
pression of Nanog and Lefty1. In the case of Nanog, our
data suggest that expression of this gene requires BRD4
binding to the promoter and that this is itself dependent on
histone acetylation. Based on the fact that the aberrant
phenotype of Mof-deficient ESCs, namely defective self-
renewal and induction of differentiation, is rescued by Na-
nog expression, we speculate that Mof normally acts to
maintain transcriptional activity of the Nanog promoter
through acetylation at H4K16 and this facilitates recruitment
of BRD4. The rapid induction of differentiation induced
by JQ1 suggests that ESC pluripotency is critically depen-
dent on BRD4 binding at the Nanog locus to maintain its
expression. Given the considerable overlap in signaling
networks that exist between ESCs and cancer stem cells
[38–40], our results are potentially pertinent not only to
understanding ESC self-renewal and pluripotency, but also
for novel cancer-directed therapies based on BET bromo-
domain inhibition.
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